On this page ▾
Key takeaways
- DB-OTO is a one-off gene therapy for deafness caused by OTOF gene changes.
- In a published trial of 12 children, 9 reached the main hearing target and 3 reached normal hearing.
- The US FDA granted it accelerated approval in April 2026, under the name Otarmeni.
- OTOF changes cause roughly 1 to 8% of congenital hearing loss, so few children are eligible.
- Hearing aids and cochlear implants remain the main options for most deaf children.
DB-OTO is a gene therapy for deafness caused by changes in the OTOF gene. In a published trial of 12 children, 9 reached the trial’s main hearing target after a single treatment, and 3 reached average normal hearing1. In April 2026 the US Food and Drug Administration granted it accelerated approval, under the name Otarmeni, for hearing loss linked to OTOF2.
The treatment, developed by Regeneron Pharmaceuticals, delivers a working copy of the OTOF gene into the cochlea. It is the first gene therapy approved in the US for a genetic form of hearing loss. Hearing aids and cochlear implants help many children, but they do not correct the underlying gene change.
Genetic causes account for up to 60% of congenital and early-onset hearing loss, but OTOF changes cause only about 1 to 8% of congenital cases3.
What did the DB-OTO trial find?
The trial, a phase 1/2 study published in the New England Journal of Medicine, treated 12 children aged 10 months to 16 years with profound hearing loss from OTOF changes. Nine reached the trial’s main hearing target at 24 weeks, an average hearing threshold of 70 dB or better, and three reached average normal hearing sensitivity1. None of the reported side effects led a child to leave the trial.
Parents described emotional first reactions as their children turned toward voices or smiled at new sounds, and several began to develop speech after treatment. These were small numbers in an early-stage trial, and results varied from child to child.
How does the therapy work?
The OTOF gene makes otoferlin, a protein the inner ear’s hair cells need to pass sound signals to the brain. DB-OTO delivers a working copy of the gene into the cochlea in a single infusion, using a harmless virus as the carrier. In the trial it improved hearing in most children, but how long the benefit lasts is still being studied.
What is the clinical evidence so far?
The published results come from the early part of Regeneron’s CHORD trial, which is continuing1. Because the approval is accelerated, the company must confirm the benefit with more data, and the FDA has asked for results from at least 30 patients2. Families and clinicians will be watching how well and how long the improvements last.
What happens next?
Researchers stress the need for long-term follow-up to confirm how long the improvements last and to keep monitoring safety. OTOF changes are rare, so the therapy will suit only a small group of children. Gene therapy for other types of genetic deafness is still at the research stage.
“This work is exciting because it targets the root cause of deafness rather than compensating for it,” said Jessica Tovey, an audiologist at Hearology. “Families should know that the results are promising, but the evidence is still early and long-term follow-up continues.”
Not every child with profound deafness has an OTOF change, and a genetic test is how it is found. For children who are not eligible, hearing aids and cochlear implants remain the main options. You can read more about gene therapy research in our articles on the early safety trial for childhood deafness and a new gene therapy target for hearing and balance.

Frequently asked questions
What is DB-OTO gene therapy?
Can gene therapy cure deafness?
Is DB-OTO approved in the UK?
Can deafness be inherited?
How common is OTOF-related deafness?
References:
- [1] V. Valayannopoulos et al., "DB-OTO gene therapy for inherited deafness," New England Journal of Medicine, vol. 394, no. 11, pp. 1074-1083, 2026, doi: 10.1056/NEJMoa2400521. [Online]. Available:
- [2] U.S. Food and Drug Administration, "FDA approves first-ever gene therapy treatment for genetic hearing loss under national priority voucher," press announcement, Apr. 2026. Accessed: Nov. 16, 2026. [Online]. Available:
- [3] National Institute on Deafness and Other Communication Disorders, "The future of gene therapy for hearing loss," NIDCD. Accessed: Nov. 15, 2026. [Online]. Available:
